Stereotactic Body Radiation Therapy (SBRT) Combined with Chemotherapy for Unresected Pancreatic Adenocarcinoma

Marie K. Gurka, Christine Kim, Aiwu Ruth He, Aline Charabaty, Nadim Haddad, Jenna Turocy, Lynt Johnson, Patrick Jackson, Louis M. Weiner, John L. Marshall, Sean P. Collins, Michael J. Pishvaian, Keith Unger

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: The role of radiation therapy in the management of unresectable pancreatic cancer is controversial. One concern about concurrent chemoradiation relates to the timing of chemotherapy. In contrast to conventional radiation therapy, stereotactic body radiation therapy (SBRT) delivers high doses in a shorter duration resulting in minimal disruption in chemotherapy. Here, we report our results of patients treated with SBRT and chemotherapy for inoperable pancreatic cancer. Materials and Methods: Thirty-eight patients treated with SBRT and chemotherapy for locally advanced, borderline resectable, and medically inoperable pancreatic cancer at our institution from January 2008 to December 2012 were included in this retrospective analysis. Treatment was delivered in 5 fractions of 5 or 6 Gy per fraction over 5 days. Toxicities were scored using the Common Terminology Criteria for Adverse Events version 3. Survival was calculated using the Kaplan-Meier method. Results: The median age was 70 years (range, 45 to 90 y). Eastern Cooperative Oncology Group performance status ranged from 0 to 3. Thirty-four patients received concurrent chemotherapy. Four patients received sequential chemotherapy. Median overall survival was 14.3 months and median progression-free survival was 9.2 months from diagnosis. From radiation, overall survival and progression-free survival were 12.3 and 6.8 months, respectively. The overall local control rate was 79%. Acute toxicity was minimal. Severe late SBRT-related toxicities included 1 grade 3 gastric outlet obstruction, 1 grade 4 biliary stricture, and 1 grade 5 gastric hemorrhage. Conclusions: SBRT combined with chemotherapy for unresectable pancreatic cancer is convenient, feasible, and generally well tolerated. Outcomes of SBRT combined with chemotherapy compare favorably to results obtained with chemotherapy and conventional radiation therapy.

Original languageEnglish (US)
Pages (from-to)152-157
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume40
Issue number2
DOIs
StatePublished - 2017
Externally publishedYes

Keywords

  • gemcitabine
  • mFOLFOX
  • pancreatic cancer
  • radiation
  • stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Stereotactic Body Radiation Therapy (SBRT) Combined with Chemotherapy for Unresected Pancreatic Adenocarcinoma'. Together they form a unique fingerprint.

Cite this